CEO: Charles M. Baum

Sector: Health Technology
Industry:Biotechnology

Exchange: NASDAQ

Country: US

Description: Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.


Key numbers

Market Capitalization:5066446216
Shares Outstanding: 43642400
Float: 42992521
Next Earning Date:2020-11-04
TTm EPS: -6.503
TTm Dividend Rate:
200 days moving average:97.85
50 days moving average: 111.31
One day percent Change: -0.25



2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,